NCT06586658View on ClinicalTrials.gov

Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed/Metastatic CD70+ Inoperable Renal Cells

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 6, 2024

Primary Completion Date

July 16, 2027

Study Completion Date

July 16, 2027

Conditions
Renal Cell Carcinoma
Interventions
BIOLOGICAL

anti-CD70-CAR-T cells

The subjects received infusions of anti-CD70 CART cells following completion of lymphodepleting preconditioning chemotherapy. Dosage: 3×10\^6 cells/Kg; 1×10\^7 cells/Kg; 2×10\^7 cells/Kg.

Trial Locations (1)

201109

RECRUITING

Changzheng hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai First Song Biotechnology Co., LTD

INDUSTRY

lead

Shanghai Changzheng Hospital

OTHER

NCT06586658 - Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed/Metastatic CD70+ Inoperable Renal Cells | Biotech Hunter | Biotech Hunter